Simple Amino Acid Helps Calm The Alzheimer’s Brain in Mice

A familiar dietary amino acid is quietly doing something radical in the lab, easing some of the core brain changes that define Alzheimer’s disease. In new experiments from Kindai University, oral arginine blunted sticky amyloid buildup and brain inflammation in animals engineered to develop Alzheimer’s like pathology, while also improving their behavior.

In work published online on October 30, 2025, in Neurochemistry International, researchers led by graduate student Kanako Fujii and Professor Yoshitaka Nagai at Kindai University’s Faculty of Medicine tested arginine, a clinically approved amino acid, in a series of in vitro assays, fruit fly models, and App_NL-G-F knock in mice. They report that oral arginine supplementation suppressed amyloid beta (Aβ) aggregation, reduced plaque deposition, eased neuroinflammation, and partially rescued behavioral abnormalities, positioning arginine as a low cost, disease modifying drug candidate for Alzheimer’s disease.

Before the promise sweeps too far, the authors also draw a bold line around the limits of this work. The dose used in mice was extremely high, equivalent to nearly 1,000 milligrams per kilogram per day for a human adult, which is roughly twice the maximum oral dose approved in Japan for metabolic disorders. Such a regimen is not feasible or recommended for people, and the team stresses that their protocol does not translate to over the counter supplements. Moreover, the animal models lack key features of human Alzheimer’s, including tau tangles and neuron loss, and both rely on a rare Arctic mutation in the Aβ sequence. These caveats set a hard boundary: this is proof of concept biology, not an imminent therapeutic path.

Alzheimer’s disease affects more than 50 million people worldwide and is marked by two pathological signatures in the brain, extracellular Aβ plaques and intracellular tangles of tau protein. Recent monoclonal antibodies that target Aβ, such as lecanemab and donanemab, can clear some amyloid, but their real world benefits remain modest and they come with high costs and safety concerns related to amyloid related imaging abnormalities. The Kindai team went looking for a different kind of intervention, a safe “chemical chaperone” that could keep Aβ from clumping in the first place.

Arginine was a natural candidate. The same group had previously shown that it can stabilize misfolded polyglutamine proteins and improve symptoms in animal models of polyglutamine diseases, with hints of benefit in a phase 2 trial for spinocerebellar ataxia type 6. Because arginine is already used clinically in Japan for metabolic disorders and is known to cross into the brain, the researchers wondered whether it could also rein in Aβ, which sits upstream in the cascade of Alzheimer’s pathology.

From Test Tubes To Tiny Brains

The team began in vitro, incubating the Aβ42 peptide at body temperature and tracking its aggregation with Thioflavin T, a fluorescent dye that lights up in the presence of amyloid fibrils. As expected, Aβ42 alone produced a sharp rise in fluorescence. When the researchers added arginine, that signal dropped in a clear dose dependent fashion, with about an 80 percent reduction in aggregation at 1 millimolar arginine. Electron microscopy confirmed that amyloid fibrils formed in the presence of arginine were shorter and altered, similar to those seen with the known anti aggregation compound EGCG.

Next, they moved into a Drosophila model that expresses human Aβ42 carrying the Arctic E22G mutation in the eye. These flies normally accumulate Aβ deposits in the developing retina and show pronounced eye shrinkage from Aβ toxicity. Flies raised on food containing arginine showed far less Aβ staining in their larval eye discs and, crucially, larger, healthier looking compound eyes as adults. The protection scaled with dose, and arginine did not change Aβ transgene expression, pointing directly toward aggregation control rather than lower production.

“What makes this finding exciting is that arginine is already known to be clinically safe and inexpensive, making it a highly promising candidate for repositioning as a therapeutic option for AD.”

Armed with those results, the researchers turned to App_NL-G-F knock in mice, which carry three familial Alzheimer’s mutations in the APP gene and gradually accumulate Aβ42 plaques in cortex and hippocampus. Male mice received 6 percent arginine in their drinking water starting at five weeks of age, a regimen the group had previously shown raises arginine levels in both serum and brain without harming weight gain or fluid intake.

By six months of age, brain sections from arginine treated App_NL-G-F mice showed visibly fewer Aβ plaques across the cortex and hippocampus compared with untreated animals. Quantitative image analysis confirmed that both plaque area and plaque number were reduced. Staining with a dense core amyloid dye, FSB, revealed a particularly striking drop in compact core plaques, hinting that arginine slows the maturation of fibrillar deposits rather than merely trimming their edges.

Biochemical assays told a similar story. Insoluble Aβ42 extracted from the cortex, representing aggregated species that require guanidine hydrochloride to dissolve, was substantially lower in arginine treated mice, while soluble Aβ42 levels in tris buffered saline were unchanged. Arginine did not alter APP gene expression, nor did it impact insoluble Aβ40, pointing to a selective effect on Aβ42 aggregation dynamics rather than global APP processing.

Behavior, Brain Inflammation, And The Road Ahead

Pathology alone does not capture the human toll of Alzheimer’s disease, so the team asked whether arginine’s biochemical benefits translated into functional gains. In the Y maze test, App_NL-G-F mice typically show reduced spontaneous activity as the disease progresses. At nine months, arginine treated knock in mice traveled farther and entered more arms than their untreated counterparts, suggesting partial rescue of activity related deficits. Improvements at six months were more modest, and the researchers note considerable variability between individual animals, which may have limited their ability to detect earlier behavioral effects.

Neuroinflammation is another key piece of the Alzheimer’s puzzle. In App_NL-G-F mice, rising Aβ load is accompanied by elevated expression of inflammatory cytokine genes such as Il1b, Il6, and Tnf. Arginine brought those levels down at both six and nine months, while leaving cytokine expression unchanged in wild type mice. That pattern fits a model in which arginine first interferes with Aβ aggregation, then indirectly cools inflammatory signaling that responds to amyloid deposits.

“Our findings open up new possibilities for developing arginine based strategies for neurodegenerative diseases caused by protein misfolding and aggregation,” notes Prof. Nagai.

The idea behind this work is simple but ambitious. If a safe, orally available molecule can keep misfolded proteins from clumping, it might ease or prevent diseases that begin with toxic aggregation. Arginine offers a glimpse of that possibility. But the gulf between animal models and human Alzheimer’s disease is wide. The path forward will require careful dose finding, safety studies, and trials in people who do not carry rare Arctic mutations. Until then, the findings remain a striking but early signal that a common amino acid can reshape the biology of Aβ.

Neurochemistry International: 10.1016/j.neuint.2025.106082